Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;37(4):420-9.
doi: 10.1111/apt.12182. Epub 2012 Dec 13.

Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease

M D Long  1 , C Martin, R S Sandler, M D Kappelman
Affiliations

Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease

M D Long et al. Aliment Pharmacol Ther. 2013 Feb.

Abstract

Background: Patients with inflammatory bowel disease (IBD) on certain immunosuppressants have increased herpes zoster (HZ) risk.

Aim: To determine the risk of HZ in IBD and how antitumour necrosis factor-alpha (anti-TNF) agents affect this risk.

Methods: We performed a retrospective cohort and nested case-control study using administrative data from IMS LifeLink(®) Information Assets-Health Plan Claims Database. In the cohort, we identified IBD patients <age 64 by diagnosis codes; matched to four individuals without IBD. HZ risk was evaluated by incidence rate ratio (IRR) and adjusted Cox proportional hazards models (HR). In the nested case-control analysis, 2659 IBD patients with HZ were each matched to four IBD patients without HZ. We determined associations between medications and HZ using conditional logistic regression.

Results: The cohort included 50 932 patients with Crohn's disease (CD), 56 403 patients with ulcerative colitis (UC) and 1269 with unspecified IBD, matched to 434 416 individuals without IBD. The IBD cohort had increased HZ risk compared with non-IBD (IRR: 1.68, 95% CI: 1.60-1.76). After adjustment, IBD patients had a higher risk of HZ than non-IBD (HR: 1.49, 95% CI: 1.42-1.57). In the nested case-control multivariate-adjusted analyses, anti-TNF medications (OR: 1.81, 95% CI: 1.48-2.21), corticosteroids (OR: 1.73, 95% CI: 1.51-1.99) and thiopurines (OR: 1.85, 95% CI: 1.61-2.13) were independently associated with HZ. Risk of HZ was highest with combination anti-TNF and thiopurine therapy (OR: 3.29, 95% CI: 2.33-4.65).

Conclusions: Patients with inflammatory bowel disease are at increased risk for herpes zoster. Use of thiopurines, anti-TNF agents, combination therapy and corticosteroids increases herpes zoster risk.

PubMed Disclaimer

Conflict of interest statement

Disclosures: No conflicts of interest exist for any author.

Figures

Figure 1
Figure 1
Annual Zoster Incidence (per 100,000) in Inflammatory Bowel Disease (IBD) (n=108,604) and non-IBD Populations (n=434,416), Stratified by Crohn’s disease (CD) (n=50,932) as Compared to non-CD (n=203,728) and Ulcerative Colitis (UC) (n=56,403) as Compared to non-UC (n=225,612) Populations. Footnote: Data from IMS LifeLink® Information Assets-Health Plan Claims Database (1997-2009), IMS Health Incorporated.
Figure 2
Figure 2
Annual Zoster Incidence (per 100,000) in Crohn’s disease (CD) (n=50,932) as Compared to non-CD Populations (n=203,728) and Ulcerative Colitis (UC) (n=56,403) as Compared to non-UC Populations (n=225,612), within 10 Year Strata of Age Footnote: Data from IMS LifeLink® Information Assets-Health Plan Claims Database (1997-2009), IMS Health Incorporated.
See this image and copyright information in PMC

Comment in

References

    1. Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics. 2007;25:155–69. - PubMed
    1. Straus SE, Ostrove JM, Inchauspe G, Felser JM, Freifeld A, Croen KD, Sawyer MH. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med. 1988;108:221–37. - PubMed
    1. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 2011;52:332–40. - PubMed
    1. White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics. 2009;27:781–92. - PubMed
    1. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483–90. - PubMed

Publication types